RGTL.F Stock Overview A multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Argent BioPharma Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Argent BioPharma Historical stock prices Current Share Price AU$0.12 52 Week High AU$0.57 52 Week Low AU$0.12 Beta 1.1 1 Month Change -67.60% 3 Month Change -49.30% 1 Year Change -65.32% 3 Year Change -99.58% 5 Year Change -99.53% Change since IPO -99.71%
Recent News & Updates
Argent Biopharma Limited Appoints Daniel Robinson as Director Nov 28 Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 28
Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 24
Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024 Sep 25 Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange Sep 23
Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. See more updates
Argent Biopharma Limited Appoints Daniel Robinson as Director Nov 28 Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 28
Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 24
Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024 Sep 25 Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange Sep 23
Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.
Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer May 08
Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board Apr 16 MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million. Jan 10
MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia Dec 19
MGC Pharmaceuticals Limited Announces Board Changes Dec 01 MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million. Nov 08
MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023 Oct 09
MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA® Aug 15
MGC Pharmaceuticals Limited Announces Executive Changes Jul 30
MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary Jul 29 MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million. Jul 15
MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director
MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023 May 30
MGC Pharmaceuticals Limited Announces Change of CFO Feb 03
MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm Jan 10
MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director Jan 03
MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial Dec 09
Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support Oct 25
MGC Pharmaceuticals Limited Provides an Update on Its Operations Oct 20
MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022 Oct 18
Mgc Pharmaceuticals Limited Announces Board Changes Oct 05
MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19 Sep 23
MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study Sep 21
MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022 Sep 05
MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial) Aug 15 MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC Jul 30
Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer Jul 19
MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support Jul 15
MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19 Jul 08
MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech Jul 06
MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report Jun 28
Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress Jun 24
MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer Jun 16
Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann Jun 06
MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office May 12
Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer Apr 26
MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office Apr 21
MGC Pharmaceuticals Limited Announces Executive Changes Apr 12
MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India Jan 07
Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients Dec 22
MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding Dec 02
MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding Dec 01
MGC Pharmaceuticals Limited Announces Uk Import Permit Granted for Cannepil Sep 15
MGC Pharmaceuticals Limited Announces Successful Submission of Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System Jul 15
Mgc Pharmaceuticals Limited Announces Phase Iii Cimetra Clinical Trial Commences Jul 14
MGC Pharmaceuticals Limited Announces Cannabis Derived Epilepsy Investigational Medicinal Product Jun 15
Mgc Pharmaceuticals Ltd Provides Progress Report on Major Clinical Trial Programs Planned for 2021 May 25
MGC Pharmaceuticals Ltd Announces Further Results from the Phase II Clinical and Preclinical Studies on ArtemiC(TM) May 08
MGC Pharmaceuticals Limited Revives Increased Initial Supply Agreement for ArtemiC Mar 04
MGC Pharmaceuticals Ltd Signs Master Suppy and Distribution Agreement with Swiss PharmaCan AG for Artemic Rescue Feb 18
MGC Pharmaceuticals Limited Announces New In-Vitro Cannabinoid Study on Glioblastoma Treatment Feb 16
Swiss Pharmacan AG, and MGC Pharma Report on Successful Phase II Clinical Results For COVID-19 Treatment Candidate Based on its MyCell Technology Jan 15
MGC Pharmaceuticals Ltd Appoints Nicole Godresse as Its New Global Chief Sales Officer Jan 13
MGC Pharmaceuticals Limited Announces ArtemiC Phase II Clinical Trial Results Dec 16
MGC Pharmaceuticals Limited Appoints Narelle Warren as Joint Company Secretary, Effective 30 November 2020 Nov 30
MGC Pharmaceuticals Limited (ASX:MXC) completed the acquisition of Clinical assets of Medicinal Cannabis Clinic Pty Ltd. Nov 24
MGC Pharma Progresses Successful Results from Cannabinoid Treatment of Glioblastoma Towards Clinical Trials Nov 18
MGC Pharmaceuticals Limited Announces Completion of Phase Ii Clinical Trial on Covid-19 Patients Nov 06
MGC Pharmaceuticals Limited Announces Affordable Cannabinoid Product Line Oct 20
MGC Pharmaceuticals Limited Announces the Results of A Pre-Clinical in Vivo Safety and Toxicity Study Oct 16
MGC Pharmaceuticals Ltd Announces It Has Completed the First Shipments of Its Mercury Pharma Line Which Includes the High THC Ratio Products Directly Oct 13
MGC Pharmaceuticals Limited Launches CannEpil App Oct 08
MGC Pharmaceuticals Limited announced that it expects to receive AUD 15 million in funding from Mercer Street Capital Partners, LLC Oct 06
MGC Pharmaceuticals Limited Auditor Raises 'Going Concern' Doubt Oct 04
MGC Pharmaceuticals Limited (ASX:MXC) signed a binding term sheet to acquire Clinical assets of Medicinal Cannabis Clinic Pty Ltd for AUD 1.4 million. Oct 02
MGC Pharmaceuticals Limited (ASX:MXC) completed the acquisition of an additional 6.67% stake in PANAX Pharma s.r.o. Sep 09 Shareholder Returns RGTL.F US Pharmaceuticals US Market 7D 0% 1.6% -2.2% 1Y -65.3% 9.7% 23.9%
See full shareholder returns
Return vs Market: RGTL.F underperformed the US Market which returned 23.9% over the past year.
Price Volatility Is RGTL.F's price volatile compared to industry and market? RGTL.F volatility RGTL.F Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 10.4% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: RGTL.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RGTL.F's volatility change over the past year.
About the Company Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company’s principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and RGAI03MW01, which focuses on chronic wound treatment.
Show more Argent BioPharma Limited Fundamentals Summary How do Argent BioPharma's earnings and revenue compare to its market cap? RGTL.F fundamental statistics Market cap US$5.08m Earnings (TTM ) -US$10.94m Revenue (TTM ) US$556.20k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RGTL.F income statement (TTM ) Revenue AU$891.08k Cost of Revenue AU$1.20m Gross Profit -AU$304.15k Other Expenses AU$17.23m Earnings -AU$17.53m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.32 Gross Margin -34.13% Net Profit Margin -1,967.34% Debt/Equity Ratio -149.0%
How did RGTL.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 12:32 End of Day Share Price 2024/12/02 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Argent BioPharma Limited is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Salvatore Gaetano Verdoliva Canaccord Genuity Robin Davison Capital Network by Proactive Investors Maxim Jacobs Edison Investment Research
Show 1 more analysts 
